Anatomical differences in uterine sensitivity to prostaglandin F(2alpha) and serotonin in non-pregnant rats.
The ovarian steroids regulate the sensitivity of a population of uterine receptors to prostaglandin F(2alpha), serotonin and oxytocin. However, the uterine sensitivity to prostaglandin F(2alpha) and oxytocin does not coincide with the estrogen-induced increase in the number of receptors. Anatomical differences affect the uterine sensitivity to agonists. We investigated whether anatomical differences between ovarian and cervical uterine regions modulate the hormone-regulated sensitivity to prostaglandin F(2alpha), serotonin and oxytocin. Non-cumulative concentration-response curves for these agonists were recorded for ovarian and cervical uterine segments from adult ovariectomized rats treated with 17beta-estradiol, 17beta-estradiol+progesterone, or vehicle. The ovarian segments displayed a higher maximal response (E(max)) to prostaglandin F(2alpha) and a lower E(max) to serotonin than the cervical segments. Both uterine segments displayed a similar sensitivity to oxytocin. The ovariectomized controls displayed the highest E(max) and the lowest effective concentration 50 (EC(50)) for oxytocin and prostaglandin F(2alpha). Anatomical differences between ovarian and cervical uterine regions modulate the hormonal regulation of uterine sensitivity to serotonin and prostaglandin F(2alpha) in the non-pregnant rat uterus.
Oropeza
Martha V
MV
Unidad de Investigacion en Farmacologia, Hospital de Especialidades, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Apdo. Postal 73-032, Mexico 03020, D.F., Mexico. marthavero@yahoo.com
Ponce-Monter
Hector
H
Villanueva-Tello
Teodoro
T
Palma-Aguirre
José Antonio
JA
Campos
Maria G
MG
D000818:Animals; D002584:Cervix Uteri / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology; D015237:Dinoprost / Q000494:pharmacology / Q000502:physiology*; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D009215:Myometrium / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology; D010052:Ovariectomy; D010053:Ovary / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology; D010121:Oxytocin / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D014590:Uterine Contraction / Q000187:drug effects; D014599:Uterus / Q000033:anatomy & histology* / Q000187:drug effects / Q000502:physiology*
D004338:Drug Combinations; C074283:estradiol 3-benzoate; D012701:Serotonin; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost